Healthcare / BiotechnologyKOSDAQ
$6010.00
-290.00 (-4.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
8/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.1B
P/E
N/A
•EV/EBITDA
30.0x
↑ROE
-1.1%
↓Gross Margin
70.6%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2024–2025 · 1 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
1.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $60.02B · net income $-754.9M · FCF $-1.35B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $60.02B | $60.02B | — |
| Net Income | $-754.9M | $-754.9M | $3.52B |
| EBITDA | $1.45B | $1.45B | — |
| EPS | -99.00 | -99.00 | — |
| Gross Margin | 70.6% | 70.6% | — |
| Operating Margin | 5.5% | 5.5% | — |
| Net Margin | -1.3% | -1.3% | — |
| Balance Sheet | |||
| Debt/Equity | 0.04 | 0.04 | — |
| Current Ratio | 4.75 | 4.75 | — |
| Cash Flow | |||
| Free Cash Flow | $-1.35B | $-1.35B | — |
| Returns | |||
| ROE | -1.1% | -1.1% | 6.8% |
| Valuation | |||
| EV/EBITDA | 30.02 | 30.02 | — |
| P/B | 0.66 | 0.66 | — |
| Growth & Yield | |||
| Dividend Yield | 0.7% | 0.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.4%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -99.00
Residual
-38.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.